Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 29, 2009

View Archived Issues

NIAID awards Cleveland BioLabs grant for protectan CBLB-502 research

Novel mPGES-1 inhibitors identified by NovaSAID for RA and other conditions

Perlegen Sciences launches BrevaGen breast cancer risk stratification test

FDA grants approval to Cepheid to market Xpert HemosIL FII and FV test

Abbott to acquire Solvay for EUR 4.5 billion in cash

Centocor's Stelara approved by the FDA for moderate to severe plaque psoriasis

Galapagos expands drug discovery collaboration with Schering-Plough

FDA grants priority review to sNDA of Cephalon's Nuvigil for jet lag disorder

Medivation initiates phase III MDV-3100 trial in advanced prostate cancer

BioLineRx reports final results from EAGLE trial in schizophrenia

Campath meets primary endpoint in phase III combination therapy trial for CLL

Chelsea Therapeutics reports preliminary phase III data of droxidopa for orthostatic hypotension

Keryx reports results of open-label extension study of Zerenex for hyperphosphatemia

Ticagrelor reduces cardiovascular death and heart attacks in patients with ACS

CHMP issues positive opinion for Yondelis in combination with Caelyx in ovarian cancer

Anti-RANKL antibody reduces breast cancer metastasis to bone in novel mouse model

Blocking RANK-L activity with ALX-0141, a potential treatment for bone resorption disorders

Phase II clinical benefit of everolimus in patients with recurrent endometrial carcinoma

New antimycobacterial calpinactam discovered at Kitasato University

Natural product AS-2077715 active against Trichophyton spp.

Icotinib hydrochloride safe and active in NSCLC patients in phase I/IIa trial

Boehringer Ingelheim presents MCH-R1 receptor antagonists for treating obesity

Opioid receptor antagonists for the treatment of pain presented by Alkermes

Novel compounds for the treatmemt of HCV infection claimed by Bristol-Myers Squibb

Stockholders from Raptor Pharmaceuticals and TorreyPines Therapeutics approve merger

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...